Geopolitical Risks Heighten Supply Security Concerns​

The Middle East, as a major producer of energy and certain critical chemical feedstocks such as methanol and bromine, has experienced instability affecting upstream costs and logistics routes (e.g., the Strait of Hormuz). This has intensified concerns over potential disruptions in pharmaceutical and API supplies, accelerating adjustments in supply chain strategies.

U.S., EU, and Japan Advancing “Localization” and Controllable Supply Chains​

• United States:​ Utilizing authorities under the Defense Production Act and Section 232 investigations, combining financial support with tariff adjustments, to encourage the return of key drug and API production capacity to domestic soil.
• European Union:​ Adopted the Critical Medicines Act, providing legislative backing for the construction of essential medicine production facilities within the EU, and incorporating “supply security” and “industrial resilience” criteria into public procurement assessments, promoting a “Buy European” principle.
• Japan:​ Allocating budget funds to support pharmaceutical companies in increasing reserves of specific APIs such as antibiotics, while advancing domestic API production to lower dependence on particular import sources.

India Promoting Local Manufacturing and Market Diversification​

India continues to implement its Production Linked Incentive (PLI)scheme to boost domestic production of key APIs and intermediates. It is also exploring the expansion of its pharmaceutical export promotion programs to markets such as Egypt and Jordan, aiming to enhance upstream selfsufficiency while diversifying demand channels.

​

The global API supply chain is shifting from a model centered heavily on cost efficiency toward one placing greater emphasis on security and resilience through multipolar layouts. Policies across regions share the common goals of reducing singlepoint dependency, fostering regional capacity, and building strategic reserves. However, substantial structural transformation remains a gradual process due to constraints related to cost structures, industrial ecosystems, and technical barriers.

Information Sources

1.Two months into Iran war, IRC operational costs spike by up to 50% as fuel prices rise and aid routes collapse (May 6, 2026)

2.Mideast war threatens Africa's supply of humanitarian medicine (May 8, 2026)

3.Could Trump's New Drug Tariffs Shift Pharma Supply Chain Strategy? (Apr 3, 2026)

4.Drug Manufacturing Deals Surge in Europe Despite U.S. Pharma Tariffs, with Germany Leading as Key Hub (Apr 24, 2026)

5.Addressing the Challenges of Pharmaceutical Distribution in International Markets: Turning Distribution Challenges into Strategic Dominance (Aug 28, 2025)

6.The Great Recalibration: Navigating the Shift to Non-China API Sources in 2026 (Jan 30, 2026)

Disclaimer

This article is for industry information exchange and reference only. It does not constitute any investment advice, medical advice, or business decision-making basis. The data and views presented herein are derived from publicly available authoritative sources, but we make no express or implied warranties regarding their accuracy, completeness, or timeliness. Any decisions made by readers based on this information are at their own risk.